Asia
Companies from across the globe provide updates on their businesses and pipelines.
Have you ever given it a thought that one day we will witness lab grown organs? Well, if you haven’t then this article will make you think about the future of sciences.
WuXi Biologics congratulates its partner Tychan on successful completion of the Phase 1A/1B safety and efficacy trials in Singapore for TY014, a first-in-class monoclonal antibody candidate treatment for Yellow Fever
The Dubai Government Workshop, in collaboration with the Emirates Specialty Hospital, celebrated the World Diabetes Day, which falls on November 14 of every year, to help increase public awareness on treatment methods for diabetes and other chronic diseases.
Three years after Novartis opened a $1 billion research & development facility in Shanghai, the company is shifting the focus of the site from drug discovery to commercial development.
ZEISS and Kyoto University are intensifying their cooperation and have signed a new strategic research agreement.
Global BioLife Inc, the U.S. subsidiary of Singapore eDevelopment Ltd, will present its 3F Antimicrobial Fragrance as a new method to prevent and treat Tuberculosis at the ASM Biothreats Conference, 28 to 30 January, 2020 in Arlington, Virginia.
It was a busy week for clinical trial announcements. Here’s a look.
FUJIFILM Corporation will invest 13 billion yen (about $120 million) to expand the company’s gene therapy business and establish a new Gene Therapy Innovation Center adjacent to its current facility in College Station, Texas and add about 100 jobs.
It is the first BeiGene-discovered drug to be approved.
PRESS RELEASES